Recent Analysts’ Ratings Updates for BioMarin Pharmaceutical (BMRN)

BioMarin Pharmaceutical (NASDAQ: BMRN) recently received a number of ratings updates from brokerages and research firms:

• 6/6/2026 – BioMarin Pharmaceutical was downgraded by Wall Street Zen from “buy” to “hold”.
• 5/29/2026 – BioMarin Pharmaceutical was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”.
• 5/23/2026 – BioMarin Pharmaceutical was upgraded by Wall Street Zen from “hold” to “buy”.
• 5/22/2026 – BioMarin Pharmaceutical had its price target lowered by Canaccord Genuity Group Inc. from $116.00 to $111.00. They now have a “buy” rating on the stock.
• 5/19/2026 – BioMarin Pharmaceutical had its price target lowered by Bank of America Corporation from $85.00 to $80.00. They now have a “buy” rating on the stock.
• 5/19/2026 – BioMarin Pharmaceutical is now covered by Citigroup Inc.. They set a “buy” rating and a $75.00 price target on the stock.
• 5/18/2026 – BioMarin Pharmaceutical was upgraded by Citigroup Inc. to “strong-buy”.
• 5/18/2026 – BioMarin Pharmaceutical had its price target lowered by HC Wainwright from $55.00 to $50.00. They now have a “neutral” rating on the stock.
• 5/15/2026 – BioMarin Pharmaceutical was downgraded by Weiss Ratings from “hold (c-)” to “sell (d+)”.
• 5/11/2026 – BioMarin Pharmaceutical is now covered by The Goldman Sachs Group, Inc.. They set a “neutral” rating and a $69.00 price target on the stock.
• 5/7/2026 – BioMarin Pharmaceutical had its price target raised by Canaccord Genuity Group Inc. from $104.00 to $116.00. They now have a “buy” rating on the stock.
• 5/5/2026 – BioMarin Pharmaceutical had its price target lowered by Sanford C. Bernstein from $94.00 to $82.00. They now have an “outperform” rating on the stock.
• 5/5/2026 – BioMarin Pharmaceutical had its price target lowered by Morgan Stanley from $120.00 to $119.00. They now have an “overweight” rating on the stock.
• 5/5/2026 – BioMarin Pharmaceutical had its “sector perform” rating reaffirmed by Royal Bank Of Canada. They now have a $66.00 price target on the stock.
• 5/5/2026 – BioMarin Pharmaceutical had its “neutral” rating reaffirmed by HC Wainwright. They now have a $55.00 price target on the stock.
• 5/1/2026 – BioMarin Pharmaceutical was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”.
• 4/27/2026 – BioMarin Pharmaceutical is now covered by Morgan Stanley. They set an “overweight” rating and a $120.00 price target on the stock.
• 4/16/2026 – BioMarin Pharmaceutical was downgraded by Weiss Ratings from “hold (c-)” to “sell (d+)”.

Insiders Place Their Bets

In related news, EVP Gregory R. Friberg sold 3,281 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $53.85, for a total transaction of $176,681.85. Following the transaction, the executive vice president owned 51,818 shares of the company’s stock, valued at $2,790,399.30. This trade represents a 5.95% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.85% of the stock is owned by insiders.

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.